Concerning T2D therapy, 87 (42.4%) subjects were on oral hypoglycemic agents (OHA) alone, 17 (8.3%) subjects were on only insulin, and 101 (49.2%) patients were in treatment with a combination of 2 or more drugs (including insulin); in particular, regarding innovative drugs, 60 patients (29.2%) were on Glucagon-like peptide-1 receptor agonist (GLP-1RAs) and 26 (12.6%) on SGLT2 inhibitors (SGLT2i). This evidence concerns the gene INS and type 2 diabetes mellitus.